Vaxart is focused on developing oral recombinant protein vaccines administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies have been completed; seasonal influenza, for which a Phase 2 challenge study was recently completed; and respiratory syncytial virus, or RSV, a common cause of respiratory tract infections. In addition, Vaxart has two programs targeting human papillomavirus, or HPV. The Company is developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18, and is also in Phase 2 with BTA074, an antiviral treatment for condyloma caused by HPV types 6 and 11.
Copyright Nasdaq. Minimum 15 minutes delayed.